Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

October 16, 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in ​uterine and soft tissue leiomyosarcoma.

Patricia Pautier, MD, head of the Medical Day Hospital Unit at the Institut Gustave Roussy Cancer Campus, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin (Yondelis) in ​uterine and soft tissue leiomyosarcoma.

The secondary end point of the LMS-02 study was to evaluate overall survival (OS) after a medium follow-up of 7 years, says Pautier. The updated results were encouraging, reflecting a median OS of about 34.4 months in the entire population. The results were less impressive in patients with uterine leiomyosarcoma with a median OS of 27.5 months, adds Pautier. However, the median OS was 38.7 months in patients with soft tissue leiomyosarcoma.

Additionally, two phase 3 studies that were done in the first-line setting in the same patient population showed a median OS ranging from 22 to 29 months with doxorubicin alone or doxorubicin in combination with another agent in patients with soft tissue sarcoma, adds Pautier.

Now, a phase 3 study (NCT02997358) is comparing doxorubicin alone versus the combination of doxorubicin and trabectedin followed by trabectedin in patients who do not progress after 6 cycles of treatment. The results from this research are pending and will be read out soon, concludes Pautier.


x